Evaluate

Research Company/Group
We believe that connected data leads to a clearer picture. We help clients can make accurate, high value decisions that ensure therapies get to the patients faster. Our seamless view of the industry builds your understanding of the commercial issues that affect strategic decisions — so you can turn understanding into insight, and insight into action. From market sizing and commercial opportunity assessment, to competitive intelligence and deal benchmarking, Evaluate is here to help. Our insights solutions put the data you need at your fingertips, while our experts are here to deliver tailored guidance. Evaluate is proud to be part of Norstella – an organisation that unites five market-leading companies with a shared goal: to improve patient access to life-changing therapies. We are stronger together – and as Norstella company, Evaluate plays a key role in helping you connect the dots from pipeline to patient. Source

Actions

Share this page

Media Outlet details

Scope International, Trade/B2B
Language English
Country United Kingdom
Similarweb UVMSimilarweb UVM Request pricing
Comscore UVMComscore UVM Request pricing

Recent Articles

Search

Patents, Politics, and AI: The Conversations Shaping BIO 2026

| Evaluate
Skip to content Over 20,000 biopharma professionals gathered in San Diego for four days of dealmaking, debate, and a few hard truths about where the industry is headed. Evaluate’s BIO International 2026 infographic pulls together the numbers, the buzzwords, and the quotes that defined the conversation, from the patent cliff driving M&A to the question of whether AI can really be trusted with drug discovery decisions.
Open in Who Shared Issue with article?

2026 Post-ASCO Sample Report

| Evaluate
ASCO 2026 is over. Here’s what it means for your pipeline and your portfolio. The 2026 ASCO Annual Meeting brought a wave of new oncology data, from bladder cancer ADCs to next-generation breast and lung cancer therapies. Sorting through hundreds of abstracts and presentations takes time most teams don’t have. Our Post-ASCO Report breaks down the data that matters, drug by drug and indication by indication, with analyst commentary on what it means clinically and commercially.
Open in Who Shared Issue with article?

Norstella Atlas | Agentic AI for Biopharma

| Evaluate
Atlas works from Norstella’s proprietary data, curated by pharma analysts for decades, and integrates your own data and proprietary insights alongside it. Upload internal forecasts, KOL transcripts, and proprietary assumptions, securely firewalled, never shared, never used to train the model. Your internal data is treated as a peer to Norstella’s, not a secondary input. The output reflects your team’s unique point of view; built on the trusted foundation your industry already relies on.
Open in Who Shared Issue with article?

Evaluate Recognized for Artificial Intelligence Innovation in 9th Annual AI Breakthrough Awards Program

| Evaluate
Ninth Annual Program Honors the AI Innovators Shaping the Next Era of Global Innovation LONDON, June 25, 2026 – Evaluate, a Norstella company and the leading global provider of market insights for the pharmaceutical industry, today announced that Ask Ella has been named “Enterprise AI Search Solution of the Year” in the 9th annual AI Breakthrough Awards program.
Open in Who Shared View Duplicates (65) Issue with article?

Evaluate Releases Annual World Preview Report Revealing Updated Market Forecasts for the Pharmaceutical Industry

| Evaluate
LONDON – 23 June 2026 – Evaluate, the leading provider of market insights for the pharmaceutical industry, today released its 2026 World Preview Report, providing updated insights for the global pharmaceutical market. The 2026 iteration forecasts that worldwide prescription drug sales will surpass $2 trillion in 2032, with compounded annual growth between 2025-2032 topping 7%.
Open in Who Shared View Duplicates (94) Issue with article?

World Preview 2026: Big Drugs. Bigger Questions.

| Evaluate
Global prescription drug sales are forecast to exceed $2 trillion by 2032, driven by a new era of obesity and autoimmune blockbusters, sustained M&A activity, and a dealmaking landscape that is shifting quickly. Growth remains strong and the R&D pipeline is healthy. But pricing pressure, regulatory uncertainty, and China’s emergence as the dominant source of licensed pipeline assets are raising urgent questions about where value will be created next.
Open in Who Shared Issue with article?

ASCO 2026: 6 Key Commercial Trends in Oncology

| Evaluate
Skip to content ASCO 2026 confirmed that oncology is entering a new phase, one defined less by whether new therapies work, and more by how to sequence them, who gets access, and what comes next. Across hematology, breast cancer, lung cancer, and gynecological tumors, the data raised as many commercial questions as it answered. In vivo CAR-T posted its first multi-patient proof of concept. Keytruda faced its most credible competitive challenge yet in first-line NSCLC.
Open in Who Shared Issue with article?

World Preview 2026: A $2tn Industry at a Glance

| Evaluate
The infographic covers the top-selling drugs and companies in 2032, the therapy areas growing fastest, and the dealmaking picture for companies most exposed to loss of exclusivity.
Open in Who Shared Issue with article?

How to value a biotech

|
By Mike Joynes
| Evaluate
Unlike mature pharmaceutical companies, many biotech companies have few or no marketed products. Their valuation often depends on what their pipeline could become, how likely key assets are to succeed, and whether the future market opportunity supports the current investment case. For many pre-revenue biotech companies, the route to value is not always taking a product to market independently.
Open in Who Shared Issue with article?

2026 ASCO Weekend Update

| Evaluate
Skip to content The 2026 Biomedtracker/Datamonitor Healthcare ASCO Weekend Update delivers independent expert analysis on the most consequential clinical trial data presented at ASCO annual meeting, covering key drugs across major oncology indications, with likelihood-of-approval ratings and commercial commentary you won’t find in the abstracts alone.
Open in Who Shared Issue with article?

Evaluate Journalists

Fagg, Joanne